Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder

European Urology

Volumn 45, Issue 4, 2004, Pages 465-470

  Canda, A Erdem ^a   Tuzel, Emre ^a   Mungan, M Ugur ^a   Yorukoglu, Kutsal ^a   Kirkali, Ziya ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

BCG; Bladder; Carcinoma in situ; Intravesical treatment; Prostatic urethral involvement; Transitional cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; EPIRUBICIN;

ADULT; AGED; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA; NEPHROURETERECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; STROMA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URETHRA CARCINOMA; URINARY TRACT CANCER;

EID: 1642274526     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.12.014     Document Type: Article

References (23)

1. Freeman J.A., Esrig D., Stein J.P., Skinner D.G. Management of the patient with bladder cancer. Urerhral recurrence. Urol. Clin. North Am. 21(4):1994;645-651.
2. Hardeman S.W., Soloway M.S. Transitional cell carcinoma of the prosate: diagnosis, staging and management. World J. Urol. 6:1988;170-174.
3. Pagano F., Bassi P., Ferrante G.L., Piazza N., Abatangelo G., Pappagallo G.L.et al. Is pT4a (D1) stage reliable in assessing transitional cell carcinoma involvement of the prostate in patients with concurrent bladder cancer? A necessary distinction for contiguous and noncontiguous involvement. J. Urol. 155:1996;244-247.
4. Hillyard R.W., Ladaga L., Schellhammer P.F. Superficial transitional cell carcinoma carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guèrin. J. Urol. 139:1988;290-293.
5. Schellhammer P.F., Ladaga L.E., Moriarty R.P. Intravesical bacillus Calmette-Guèrin for treatment of superficial transitional cell carcinoma of prostatic urethra in association with carcinoma of the bladder. J. Urol. 153:1995;53-56.
6. Palou J., Xavier B., Laguna B., Montlleo M., Vicente J. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guèrin therapy without previous transurethral resection of the prostate. Urology. 57:1996;482-484.
7. Bretton P.R., Herr H.W., Whitmore W.F. Jr., Badalament R.A., Kimmel M., Provet J.et al. Intravesical bacillus Calmette-Guèrin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J. Urol. 141:1989;853-856.
8. Orihuela E., Herr H.W., Whitmore W.F. Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG. Urology. 34(5):1989;231-237.
9. Solsona E., Iborra I., Ricos J.V., Monros J.L., Dumont R., Casanova J.et al. Recurrence of superficial tumors in prostatic urethra. Eur. Urol. 19:1991;89-92.
10. Sobin HL, Wittekind C., editors. Urogenital Tumours. TNM Classification of Malignant Tumours. New York: Wiley; 1997. p 180.
11. Thelmo W.L., Seemayer T.A., Madarnas P., Mount B.M., Mackinnon K.J. Carcinoma in situ of the bladder with associated prostatic involvement. J. Urol. 111:1974;491-494.
12. Seemayer T.A., Knaack J., Thelmo W.L., Wang N.S., Ahmed N.M. Further observations on carcinoma in situ of the urinary bladder: silent but extensive intraprostatic involvement. Cancer. 36:1975;514-520.
13. Herr H.W., Pinsky C.M., Whitmore W.F. Jr., Sogani P.C., Oettgen H.F., Melamed M.R. Long term effect of intravesical bacillus Calmette-Guèrin on flat carcinoma in situ of the bladder. J. Urol. 135(2):1986;265-267.
14. Hardeman S.W., Perry A., Soloway M.S. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder. J. Urol. 140(2):1988;289-292.
15. Lockhart J.L., Chaikin L., Bondhus M.J., Politano V.A. Prostatic recurrences in the management of superficial bladder tumors. J. Urol. 130(2):1983;256-257.
16. Ratliff T.L., Kavoussi L.R., Catalona W.J. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J. Urol. 139(2):1988;410-414.
17. Stilmant M., Siroky M.B., Johnson K.B. Fine needle aspiration of granulomatous prostatitis induced by BCG immunotherapy of bladder cancer. Acta Cytol. 29(6):1985;961-966.
18. Lamm D.L., Stogdill B.J., Crispen R.G. Complications of bacillus Calmette-Guèrin immumotherapy in 1278 patients with bladder cancer. J. Urol. 135:1986;272-274.
19. Haaff EO, Catalona WJ, Ratliff TL. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.
20. Matzkin H., Soloway M.S., Hardeman S. Transitional cell carcinoma of the prostate. J. Urol. 146:1991;1207-1212.
21. Palou J., Salvador J., Parada R., Chéchile G., Millán M., Vicente J. Carcinoma in situ of the prostatic urethra: the role of intravesical BCG. Urol. Integr. Invest. 6:2001;165-170.
22. Solsona E., Iborra I., Ricos J.V., Monrós J.L., Casanova J.L., Almenar S. The prostate involvement as prognostic factor in patients with superficial bladder tumors. J. Urol. 154:1995;1710-1713.
23. Palou J., Xavier B., Laguna P., Montlleó M., Vicente J. In situ transitional cell carcinoma involvement of the prostatic urethra: bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate. Urology. 47:1996;482-484.